Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models Reveals Possible Driver Mutations Underlying Tumor Progression

• Tao Xie ,

  * E-mail: tao.xie@pfizer.com (TX); mhidalgo@cnio.es (MH)

  Affiliation Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America

  ⨯
• Monica Musteanu,

  Affiliation CNIO (Spanish National Cancer Research Centre), E-28029, Madrid, Madrid, Spain

  ⨯
• Pedro P. Lopez-Casas,

  Affiliation CNIO (Spanish National Cancer Research Centre), E-28029, Madrid, Madrid, Spain

  ⨯
• David J. Shields,

  Affiliation Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America

  ⨯
• Peter Olson,

  Affiliation Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America

  ⨯
• Paul A. Rejto,

  Affiliation Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America

  ⨯
• Manuel Hidalgo

  * E-mail: tao.xie@pfizer.com (TX); mhidalgo@cnio.es (MH)

  Affiliation CNIO (Spanish National Cancer Research Centre), E-28029, Madrid, Madrid, Spain

  ⨯